Kura Oncology reports Phase 1a data on darlifarnib combo in RCC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Kura Oncology reports Phase 1a data on darlifarnib combo in RCC

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

July 27, 2026 6:32 AM EDT

Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients

Activity compares favorably with historical outcomes for TKI and HIF-2 monotherapies -

Combination was well tolerated and safety profile consistent with reported profiles of the individual agents

Findings support potential for darlifarnib to enhance activity of VEGFR-targeted therapies in second- and third-line RCC settings

Global, randomized Phase 1b study underway to establish recommended Phase 3 dose

... More